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Background
The EVI1 gene (3q26) codes for a zinc finger transcription factor with important roles in both
mammalian development and leukemogenesis. Over-expression of EVI1 through either 3q26
rearrangements, MLL fusions, or other unknown mechanisms confers a poor prognosis in acute
myeloid leukemia.
Design and Methods
We analyzed the prevalence and prognostic impact of EVI1 over-expression in a series of 476
patients with acute myeloid leukemia, and investigated the epigenetic modifications of the
EVI1 locus which could be involved in the transcriptional regulation of this gene.
Results
Our data provide further evidence that EVI1 over-expression is a poor prognostic marker in
acute myeloid leukemia patients less than 65 years old. Moreover, we found that patients with
no basal expression of EVI1 had a better prognosis than patients with expression/over-expres-
sion (P=0.036). We also showed that cell lines with over-expression of EVI1 had no DNA
methylation in the promoter region of the EVI1 locus, and had marks of active histone modifi-
cations: H3 and H4 acetylation, and trimethylation of histone H3 lysine 4. Conversely, cell lines
with no expression of EVI1 have DNA hypermethylation and are marked by repressive
trimethylation of histone H3 lysine 27 at the EVI1 promoter.
Conclusions
Our results identify EVI1 over-expression as a poor prognostic marker in a large, independent
cohort of acute myeloid leukemia patients less than 65 years old, and show that the total
absence of EVI1 expression has a prognostic impact on the outcome of such patients.
Furthermore, we demonstrated for the first time that an aberrant epigenetic pattern involving
DNA methylation, H3 and H4 acetylation, and trimethylation of histone H3 lysine 4 and his-
tone H3 lysine 27 might play a role in the transcriptional regulation of EVI1 in acute myeloid
leukemia. This study opens new avenues for a better understanding of the regulation of EVI1
expression at a transcriptional level.
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Introduction
The EVI1 gene (3q26) codes for a zinc finger transcrip-
tion factor with important roles in both mammalian
development and leukemogenesis. Since the identifica-
tion of EVI1 as a common murine locus of retroviral inte-
gration in myeloid tumors1 this evolutionarily conserved
gene has been implicated in human myeloid disorders,
and in the development and progression of high-risk
acute myeloid leukemia (AML).2,3 Recurrent 3q26
rearrangements are the only known mechanisms that
lead to EVI1 over-expression;4-7 however, over-expression
of this gene has been reported in 9-20% AML with no 3q
aberrations, where it is also associated with an unfavor-
able outcome.8-13 Moreover, a recent study showed that
MLL-ENL activates the transcription of Evi1.7
Transcriptional activation of EVI1 through chromosome
rearrangements or other yet to be identified mechanisms,
therefore, leads to particularly aggressive forms of human
myeloid leukemia.2,3 The EVI1 locus gives rise to several
alternatively spliced variants,2,3,14,15 including the inter-
genic splicing MDS1EVI1which codes for a larger protein
with a PR domain.3,16 Besides, EVI1 is transcribed into sev-
eral 5’-end mRNA transcripts that have the same transla-
tion start site (Online Supplementary Figure S1).
To date, only three studies in large series of AML
patients have analyzed the prevalence and prognostic
value of EVI1 over-expression, discriminating EVI1 from
MDS1EVI1 (Online Supplementary Table S1).8-10,17 The first
study found that EVI1-1D was over-expressed in 13.7%
cases, and was significantly associated with shorter over-
all and event-free survival.8 Two recent studies, one by
the same group, included the analyses of other EVI1 5’-
end transcripts and confirmed the prevalence and the
poor impact that EVI1 over-expression has in AML.9,10
Lately, this group has proposed a diagnostic assay that
quantifies all EVI1 5’-end transcripts, including
MDS1EVI1. In this study, high expression of
EVI1/MDS1EVI1 was found in 10.7% cases, and predict-
ed adverse disease-free and event-free survival.17
Our aim was to study the prevalence of EVI1 over-
expression and its impact on survival in a large series of
AML patients, and to investigate the mechanisms of reg-
ulation of EVI1. We performed extensive analyses in both
cell lines and patients’ samples to investigate the genetic
and epigenetic mechanisms that could control the expres-
sion of EVI1 in AML. Our results open new avenues to a
better understanding of the prognostic impact of EVI1 in
AML, and the regulation of its expression at a transcrip-
tional level.
Design and Methods
Material
Samples were obtained at diagnosis from 476 patients with
AML, other than acute promyelocytic leukemia: the details are
given in the Online Supplementary Design and Methods. Survival
analysis was performed in the 213 AML patients who were eli-
gible for treatment and were uniformly treated according to the
Spanish Pethema Co-operative Group protocol LAM99.18
Samples were taken anonymously. Normal bone marrow,
peripheral blood, and 19 samples of normal tissues from the
human total RNA Master Panel II (Clontech, Takara-BIO, CA,
USA) were used. The characteristics of the 16 myeloid cell lines
used (DSMZ, Braunschweig, Germany) are summarized in
Online Supplementary Table S2. Cell lines were cultured according
to the supplier’s recommendations.
Cytogenetic and mutation analysis
Cytogenetic and fluorescence in situ hybridization (FISH) analy-
ses were performed as previously described5 using six BAC clones:
RP11-390G14 (3q21), RP11-475N22 (GATA2), RP11-689D3
(RPN1), RP11-82C9 (EVI1), RP11-115B16 (MDS1), RP11-196F13
(TNFSF10), and a probe for chromosome 3 centromere. The PR
domain of MDS1EVI1 was amplified by reverse transcriptase
polymerase chain reaction (RT-PCR), followed by a semi-nested
reaction with specific primers (Online Supplementary Table S3).
Gene mutation analysis of FLT3 and NPM1was performed as pre-
viously described.19-21 PCR products were purified and sequenced.
Quantitative real-time reverse transcriptase
polymerase chain reaction
The RNA isolation and EVI1 quantitative real-time RT-PCR con-
ditions are described in the Online Supplementary Design and
Methods.
Analysis of the methylation status of the EVI1
and MDS1EVI1 promoter regions
DNA methylation profiling of healthy donor peripheral blood
(n=4), bone marrow (n=4) and CD34+ cells of bone marrow (n=4)
samples was performed using the HumanMethylation27 Beadchip
(Illumina, Inc., San Diego, CA, USA), according to the manufactur-
er’s instructions.22 Further details are provided in the Online
Supplementary Design and Methods. 
Methylation status of the CpG islands of EVI1 (islands 1 and 2)
and MDS1EVI1 (islands 1 and 2) was analyzed by bisulfite
sequencing PCR (Online Supplementary Table S3). DNA was modi-
fied with the CpGenomeTM DNA Modification Kit (CHEMICON,
Millipore Corporation, MA, USA). For the treatment of the cell
lines, several concentrations and time points were tested, and opti-
mal results were obtained for 10¥106 cells in 10 mL of medium,
cultured with 4 mM of 5-aza-2’-deoxycytidine (5-Aza), and 50 nM
of trichostatin A (TSA) for 4 days; controls were cultured with
dimethylsulfoxide and glacial acetic acid.
Chromatin immunoprecipitation 
HEL, TF1, OCI-AML2, NOMO-1 and MV4-11 cell lines were
subjected to chromatin immunoprecipitation in order to assess the
acetylation of H3 and H4, and the trimethylation of histone H3
lysine 4 and lysine 27 as previously described.23 Further details are
provided in the Online Supplementary Design and Methods.
Western blot analysis
Protein isolation and western blot conditions are described in
the Online Supplementary Design and Methods.
Definitions and statistical analysis
Overall survival was defined as the time from diagnosis to death
due to any cause or end of follow-up; disease-free survival as the
time from complete remission until relapse or death, whichever
occurred first; and event-free survival as the time from diagnosis
until first event, in which failure to achieve complete remission,
relapse or death were considered events. Overall, disease-free and
event-free survival rates were determined using the Kaplan-Meier
method and survival comparisons were done with the log-rank
test. Proportional hazards models were constructed to determine
whether the groups of EVI1 expression were associated with out-
come when adjusting for other prognostic variables. P values for
the significance among the cytogenetic subgroups were calculated
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using a two-tailed χ2 test. Spearman’s rho correlation coefficient
was used to calculate the correlations between the over-expres-
sion of the EVI1 5´-end variants. Statistical analyses were per-
formed using SPSS version 15.0 (SPSS Inc., IL, USA).
Results
Expression pattern of the alternative forms of EVI1
High expression of different splice-forms of EVI1 has
been implicated in the development of high-risk AML.9,10
In order to understand the mechanisms leading to EVI1
over-expression better, we first analyzed the EVI1 5′-end
variants, including MDS1EVI1, in a panel of human tis-
sues, in AML cases, and in 16 myeloid cell lines. In each
tissue, expression levels of the EVI1 transcripts were sim-
ilar, and all transcripts could be detected in normal bone
marrow, although at low levels (Online Supplementary
Figure S2). Next, we quantified the EVI1 5′-end variants in
a series of AML patients selected as a representation of the
heterogeneity of AML cases (Online Supplementary Table
S4) and in the myeloid cell lines (Online Supplementary
Table S2 and Online Supplementary Figure S3), and complet-
ed the analysis of the cell lines with investigation of the
expression of EVI1 protein. Expression levels of EVI1 tran-
scripts in both patients’ samples and cell lines correlated
with each other in a statistically significant manner (Online
Supplementary Table S5). Among the cell lines over-express-
ing EVI1, we found two groups: AML cell lines over-
expressed transcripts -1A, -1B, -1C, and -1D, whereas cell
lines with chronic myeloid leukemia in blast phase (CML-
BP) had only EVI1-1B over-expression as a common fea-
ture. Western blot analysis detected the EVI1-FL isoform
(145 kDa) in cell lines with over-expression of at least one
EVI1 transcript (Online Supplementary Table S2 and Online
Supplementary Figure S3). As an exception, MEG-01 (CML-
BC) had over-expression of EVI1-1B and no EVI1-FL pro-
tein. Moreover, we found no association between the
expression of any EVI1 transcript and the amount of pro-
tein (Online Supplementary Table S2 and Online
Supplementary Figure S3). Seven cell lines had no basal
expression of either EVI1 or MDS1EVI1 (Online
Supplementary Table S2).
The fragility of the PR domain, which is a hotspot in
both retroviral insertions and 3q rearrangements,24
prompted us to perform a mutation analysis of the PR
domain in the cell lines. We found no mutations in this
region; we did, however, detect a novel MDS1EVI1 alter-
native splice form in four cell lines. The analysis of the
panel of normal human tissues demonstrated that this
novel alternative splice form was not expressed in periph-
eral blood, but was present in most of the tissues tested
(Online Supplementary Figure S4). This form would codify
for a truncated protein of 38 amino acids; however, a sec-
ond open reading frame is possible from the EVI1 ATG
start codon in exon 3, which would codify for the Evi1-FL
protein (NCBI Accession GQ352634) (Online
Supplementary Figure S4).
Prevalence of EVI1 over-expression in patients 
with acute myeloid leukemia
Since EVI1 alternative transcript forms correlated signif-
icantly, we investigated the expression of EVI1-1D, EVI1-
1C, and MDS1EVI1 in a series of 476 AML patients (Table
1). EVI1 (-1C and/or -1D) was over-expressed in 92 out of
the 476 patients (19.3%). Table 1 shows the prevalence of
EVI1 over-expression, and its association with relevant
clinical and molecular parameters. Statistical correlations
for -1C and -1Dwere also calculated separately and yield-
ed similar results (data not shown). The prevalence of EVI1
over-expression was significantly different among the
cytogenetic prognostic groups (P<0.001). EVI1 over-
expression was found in 72% of cases with 3q rearrange-
ments, including all 25 cases with 3q26 (P<0.001). Other
cytogenetic abnormalities associated with EVI1 over-
expression were MLL translocations (P<0.001), and mono-
somy 7 (P=0.003), but not del(7q) (P=0.562). The preva-
lence of EVI1 over-expression in patients with a normal
karyotype was 7.7%, and an inverse correlation was
found between EVI1 over-expression and both trisomy 8
and NPM1 mutations; in fact, none of the patients with
either trisomy 8 (16 cases) or NPM1 mutations (79 cases)
had EVI1 over-expression.
Prognostic impact of EVI1 expression in patients
with acute myeloid leukemia
Clinical follow-up data of patients who received induc-
tion therapy and were uniformly treated were available
for 213 patients (110 males and 103 females), with a medi-
an age at diagnosis of 58 years (range, 16-83 years). The
median follow-up was 159 weeks, with a minimum of 24
weeks. The median overall survival of this cohort was
45.7 weeks (95% CI: 36.5-54.8). Kaplan-Meier analysis
showed significant differences in well-recognized risk fac-
tors such as age and cytogenetic group (P<0.001). In a
stratified analysis by age group, patients under 65 years
old with EVI1-1C over-expression had significantly lower
overall survival (P=0.005) and event-free survival
(P=0.008) (Figure 1 and Online Supplementary Figure S5),
while no significant differences were found in disease-free
survival. However, we could not confirm the independent
prognostic significance of EVI1-1C over-expression in a
multivariate model (Online Supplementary Table S6). EVI1-
1D over-expression had no significant impact on overall,
disease-free or event-free survival. Among the whole
cohort, the group of patients with EVI1 over-expression
and no MDS1EVI1 expression had the worst outcome
(P=0.017). When comparing patients with no basal expres-
sion, expression and over-expression of EVI1 in the group
of patients under 65 years old, patients with no basal
expression had a better overall survival (P=0.020) (Figure
1). Furthermore, patients with no basal expression of EVI1
had a better overall survival than patients with expres-
sion/over-expression in both the whole cohort (P=0.036)
and in the group of patients less than 65 years (P=0.005)
(Figure 1).
EVI1 over-expression and 3q26 rearrangements
For a better understanding of the role of 3q rearrange-
ments in the expression of EVI1, we characterized the
3q21q26 region by FISH, and quantified EVI1 expression
in 16 myeloid cell lines and in 25 cases with myeloid neo-
plasias. The HEL and TF-1 cell lines had over-expression of
EVI1 and several copies of probes located on 3q26; how-
ever, a similar pattern was found in NOMO-1 and OCI-
AML2, with no EVI1 expression; moreover, OCI-AML2
had an inv(3)(q21q26) (Online Supplementary Table S2 and
Online Supplementary Figure S6). In the patients’ samples,
FISH analyses showed wide heterogeneity and complex
3q rearrangements. Cases were classified into four distinct
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groups: 3q21q26, 3q26, 3q21, and other 3q aberrations.
Cases with either 3q21q26 (8 cases) or 3q26 (7 cases)
breakpoints had EVI1 over-expression, except case
21872s, the only one with breakpoints located between
the 689D3 (3q21; 128.4 Mb) and 82C9 (3q26; 168.8 Mb)
probes. Cases with other 3q rearrangements and break-
points located between these probes had no EVI1 over-
expression either (Online Supplementary Table S8). Three
cases with a single breakpoint on 3q21 had EVI1 over-
expression (25704, 24316 and 14066s). The 3q26 break-
EVI1 expression and epigenetic alterations in AML
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Figure 1. Survival analysis of a series of patients with acute myeloid leukemia according to EVI1 expression status. (A) In Kaplan-Meier analy-
sis stratified by age, patients <65 years and with EVI1-1C over-expression showed an inferior overall survival in comparison to patients with
no EVI1-1C over-expression. (B) In Kaplan-Meier analysis, patients <65 years and no basal expression of EVI1 (-1C/-1D) had a better overall
survival in comparison to patients with either expression or over-expression of EVI1, and a trend to better outcome in the global cohort. (C)
In Kaplan-Meier analysis, patients <65 years with no basal expression of EVI1 (-1C/-1D) had a better overall survival than patients with EVI1
expression/over-expression. The same results were found in the global cohort.
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points associated with EVI1 over-expression were mainly
located centromeric to EVI1 in cases with inv(3), and
telomeric to MDS1EVI1 in t(3;3) and other 3q26
rearrangements. Besides, 3q21 breakpoints associated
with EVI1 over-expression were located centromeric to
probe 390G14 (3/4 cases) (Online Supplementary Table S8).
Aberrant epigenetic pattern of EVI1 in acute myeloid
leukemia
Results showing that EVI1 over-expression sometimes
occurs irrespectively of 3q21q26 rearrangements, and the
finding that normal basal expression of EVI1 and
MDS1EVI1 was not detected in several patients’ samples
and cell lines (including OCI-AML2, with 3q21q26)
(Online Supplementary Table S2 and Online Supplementary
Figure S3) prompted us to study whether EVI1 transcrip-
tion could be regulated by epigenetic mechanisms. For the
analysis, we selected five cell lines that represented the
heterogeneity detected in patients’ samples: HEL and TF-
1 had 3q aberrations and EVI1 over-expression; OCIAML2
and NOMO-1 had 3q and no EVI1 expression; and MV4-
11 had neither 3q nor EVI1 expression (Figure 2A).
Treatment of EVI1-/MDS1EVI1- cell lines with TSA in
combination with the demethylating agent 5-Aza induced
EVI1 expression (Figure 2B), confirming our hypothesis.
The expression did not exceed the levels in peripheral
blood or bone marrow. To assess whether the aberrant
methylation status of the promoter region of the EVI1
locus was the epigenetic mechanism involved, we first
analyzed the methylation status of the CpG islands pre-
dicted in the proximal promoter region of EVI1 and
MDS1EVI1 in normal samples. High-resolution genome-
wide methylation arrays from Illumina (Infinium
HumanMethylation27 BeadChip, Illumina, CA, USA)
showed the total absence of methylation in two probes of
EVI1 and two of MDS1EVI1 in CD34+ progenitor cells
(high EVI1 expression) and normal bone marrow and
peripheral blood (very low EVI1 expression) (data not
shown). These results indicate that aberrant hypomethyla-
tion of the promoter of EVI1 is not the mechanism of EVI1
over-expression; nevertheless, this could be the mecha-
nism involved in the EVI1 gene silencing.
The methylation status of EVI1-island 1 and
MDS1EVI1-island 2 showed concordance between EVI1
and MDS1EVI1 expression: the regions were hypermethy-
lated in EVI1-/MDS1EVI1- cell lines (Figure 2C). However,
we observed no significant changes in the methylation
status of the EVI1-island 1 before or after treatment with
TSA in combination with 5-Aza (Figure 2D). This result
prompted us to analyze the trimethylation status of his-
tone H3 lysine 4 (H3K4me3) and histone H3 lysine 27
(H3K27me3), and the acetylation of histone H3 and H4.
Quantification of the amount of chromatin immunopre-
cipitated with anti-trimethyl Lys4 and Lys27 showed that
HEL and TF-1 had enrichment of the active H3K4me3 pat-
tern, while NOMO-1, MV4-11 and OCI-AML2 had the
opposite signature, a mark of the repressive pattern
H3K27me3 (Figure 3A). However, there was no difference
in the histone methylation status of the cell lines with no
expression of EVI1 after treatment with TSA and 5-Aza
(Online Supplementary Figure S7). We also observed an
enrichment of the acetylation of histones H3 and H4,
especially H3, in HEL and TF-1 (Figure 3B), and chromatin
immunoprecipitation analysis of the EVI1 promoter
showed enrichment of acetylated histones H3 and H4 in
treated cell lines (Figure 3C). The enrichment of the active
marks both in cell lines with EVI1 over-expression and
treated cell lines, strongly suggests that histone acetylation
might play a role in EVI1 expression regulation. Regarding
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Table 1. Clinical and molecular characteristics of a series of 476 patients with
AML and the association between EVI1 over-expression (-1C and/or -1D) and
clinical and genetic parameters.
                                                   N. Cases       N. EVI1-          N. EVI1+          P
EVI1 (-1C and/or -1D)                           476           384 (80.7%)        92 (19.3%)            
Sex                                                             450                   367                        83            P=0.057
Male                                                          245           192 (78.4%)        53 (21.6%)            
Female                                                    205           175 (85.4%)        30 (14.6%)            
Age                                                             445                   366                        79            P=0.002
<65 years                                                 249            192 (77%)           57 (23%)             
≥65 years                                               194           172 (88.7%)        22 (11.3%)            
Complete remission                             220                   174                        46            P=0.515
No                                                               56              46 (82%)            10 (18%)             
Yes                                                            164            128 (78%)           36 (22%)             
Diagnosis                                                 476                   384                        92                    
AML-M0                                                     34             22 (64.7%)         12 (35.3%)            
AML-M1                                                     79              72 (91%)              7 (9%)               
AML-M2                                                    126            111 (88%)           15 (12%)             
AML-M3                                                     16             15 (93.8%)           1 (6.3%)              
AML-M4                                                     62              52 (84%)            10 (16%)             
AML-M5                                                     57             47 (82.5%)         10 (17.5%)            
AML-M6                                                     25              18 (72%)             7 (28%)              
AML-M7                                                      7                4 (57%)              3 (43%)              
AML-NOS*                                              70             43 (61.4%)         27 (38.6%)            
Secondary AML                                       292                   243                        49            P=0.013
No                                                              243           209 (86.0%)        34 (14.0%)            
Yes                                                            49             34 (69.4%)         15 (30.6%)            
Prognostic group                                    476                   384                        92            P<0.001
Good                                                          55             53 (96.4%)           2 (3.6%)              
Intermediate                                          269            234 (87%)           35 (13%)             
Poor                                                         152            97 (63.8%)         55 (36.2%)            
Cytogenetic group                                  415                   329                        86                    
Normal karyotype                   No          272           197 (72.4%)        75 (27.6%)    P<0.001
                                                      Yes         143           132 (92.3%)         11 (7.7%)             
MLL (11q23) balanced          No          402            326 (81%)           76 (19%)      P<0.001
translocation
                                                      Yes          13               3 (23%)             10 (77%)             
Trisomy 8                                  No          460            368 (80%)           92 (20%)      P=0.034
                                                      Yes          16             16 (100%)                  0                    
3q aberrations                         No          372           317 (85.2%)        55 (14.8%)    P<0.001
                                                      Yes          43              12 (28%)            31 (72%)             
Monosomy 7                            No          393           317 (80.7%)        76 (19.3%)    P=0.003
                                                      Yes          22             12 (54.5%)         10 (45.5%)            
del(7q)                                     No          407            322 (79%)           85 (21%)      P=0.562
                                                      Yes           8               7 (87.5%)           1 (12.5%)             
Complex karyotype                No          345           272 (78.8%)        73 (21.2%)    P=0.626
                                                   Yes          70             57 (81.4%)         13 (18.6%)            
MDS1EVI1 over-expression                 288                   222                        66            P<0.001
No                                                              259           219 (84.6%)        40 (15.4%)            
Yes                                                            29              3 (10.3%)          26 (89.7%)            
NPM1mutated                                        223                   203                        20            P<0.001
No                                                              144            124 (86%)           20 (14%)             
Yes                                                            79             79 (100%)                  0                    
FLT3-internal tandem                           362                   329                        33            P=0.166
duplication
No                                                              295           265 (89.8%)        30 (10.2%)            
Yes                                                            67             64 (95.5%)           3 (4.5%)              
*AML-NOS: AML not otherwise specified
the MDS1EVI1 locus, we observed slight changes in the
methylation status of the MDS1EVI1 promoter in MV4-11
after treatment with TSA and 5-Aza (Figure 2D); however,
MDS1EVI1 gene expression was not induced after treat-
ment, and we found no difference in either the histone
methylation or acetylation pattern. Taken together, these
results indicate that expression of EVI1 in AML is regulat-
ed at least in part by epigenetic mechanisms.
Discussion
EVI1 has been recognized as one of the most aggressive
oncogenes associated with AML.2,3 Our results confirm
that EVI1 over-expression is an adverse prognostic factor
in AML patients, not always restricted to 3q26 aberra-
tions. Notably, we found that the total absence of EVI1
expression might have a prognostic impact on the out-
come of AML patients, and that this atypical pattern may
be regulated by epigenetic mechanisms.
Our results confirm the prevalence of EVI1 over-expres-
sion and its adverse prognostic outcome in AML in an
independent large cohort.8,10,17 For the first time, we includ-
ed quantification and survival analysis of the EVI1-1C 5’-
end variant, and found that in younger AML patients over-
expression of this transcript was a poor prognostic marker
with regards to both overall survival (P=0.005) and event-
free survival (P=0.008) (Figure 1 and Online Supplementary
Figure S5), suggesting that this variant could be a genetic
marker in this subgroup. However, the correlation could
not be confirmed in multivariate analysis. The significant
impact of EVI1 over-expression on overall survival in a
multivariate analysis was shown only in the two largest
studies – by Lugthart et al. for EVI1-1A and EVI1-1B10 and
by Groschel et al. for EVI1/MDS1EVI1 – which did not
discriminate EVI1 from MDS1EVI1 (Online Supplementary
Table S1);17 it is, therefore, possible that our sample size
was not large enough to give statistically significant
results. Of note, we found that younger AML patients
with no EVI1 expression had a significantly better out-
come than patients with either EVI1 expression or over-
expression (Figure 1), although this could not be con-
firmed in multivariate analysis. To our knowledge, this is
the first time this finding has been reported. Further stud-
ies in independent cohorts are needed to confirm the
importance of this result.
We and others have shown the association between
EVI1 over-expression and other specific cytogenetic aber-
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Figure 2. Analysis of the epigenetic status of the EVI1 locus in five myeloid cell lines. (A) Quantification of the relative expression of the EVI1
splice variants, with bone marrow as the control sample. (B) Quantification of the relative expression of EVI1 (EVI1 11-12) after treatment
with 5’Aza and TSA. Statistical significance was estimated using the non-parametric Wilcoxon’s matched pairs test; P<0.05 was considered
significant (*). (C) Diagram of the methylation status of the EVI1-Island 1 and MDS1EVI1-Island 2 by direct sequencing after bisulfite treat-
ment (white: non-methylated; black: methylated).(D) Diagram of the methylation status of the EVI1-Island 1 and MDS1EVI1-Island 2 after
treatment with 5’Aza and TSA (white: non-methylated; black: methylated). 
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rations such as MLL rearrangements and monosomy 7
(Table 1).8,10,17 Interestingly, it has been recently shown that
the specific MLL-ENL fusion activates the transcription of
Evi1 in undifferentiated hematopoietic cells.7 In addition,
in mouse models, EVI1 over-expression induces a
myelodysplastic syndrome that does not progress to
AML,25 suggesting the necessity of cooperating mutations
in the progression to AML. As demonstrated in gene ther-
apy studies, in which enforced expression of EVI1 in
human cells leads to genomic instability, monosomy 7,
and clonal progression,24,26 our results support the putative
role of monosomy 7 as a cooperating mutation in EVI1-
positive AML. A similar cooperation has been reported in
a murine model between RUNX1 mutation D171N and
EVI1 in the AML transformation of myelodysplastic syn-
drome;27 however, we found no mutations of RUNX1 in a
series of 46 cases with EVI1 over-expression (data not
shown), suggesting that this mechanism is not frequent in
human AML. Finally, we found an inverse correlation
between EVI1 over-expression and NPM1 mutations,8,10,12
in agreement with the better outcome of patients with
NPM1 mutations.28
To date, 3q rearrangements and MLL fusions are the
only known mechanisms of EVI1 over expression.
Quantitative real-time RT-PCR and FISH of 16 cell lines
and a series of samples from patients with myeloid malig-
nancies confirmed that EVI1 over-expression is associated
with 3q26, although sometimes occurs irrespective of 3q
rearrangements (Online Supplementary Table S8 and Online
Supplementary Figure S6).9,10 Moreover, the prevalence of
EVI1 over-expression among the patients with different
categories of 3q abnormalities is similar to that found in
another recent study.29 Interestingly, we showed that FISH
breakpoints in cases with 3q26 and EVI1 over-expression
were located telomeric to MDS1EVI1 (Online
Supplementary Table S8), a hotspot locus for retroviral
insertions,26 which suggests that disruption of this region
is of the foremost importance in the regulation of EVI1
transcription. We also demonstrated that the EVI1 protein
is present even if only one EVI1 transcript is over-
expressed. As an exception, MEG-01 had over-expression
of EVI1-1B and no EVI1-FL protein. In this cell line the pro-
tein levels might be low and, therefore, difficult to detect
by western blot, although in the KU-812 cell line, also
with low levels of EVI1 expression, the protein could be
detected. Another explanation might be that the accumu-
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Figure 3. Analysis of the epigenetic status of the histones of the EVI1 locus in five myeloid cell lines. (A) Quantitative real-time RT-PCR per-
formed on fragmented chromatin, showing the enrichment of trimethylation of histone H3 lysine 4 (H3K4me3) and histone H3 lysine 27
(H3K27me3) on the EVI1 promoter. (B) Quantitative real-time RT-PCR performed on fragmented chromatin, showing the enrichment of acety-
lated histones H3 and H4 on the EVI1 promoter. The results were calculated using the DDCt method. They were presented as the fold enrich-
ment of chromatin DNA precipitated by the specific antibody versus chromatin DNA precipitated by no antibody, as control. (C) Quantitative
real-time RT-PCR performed on fragmented chromatin, showing the enrichment of acetylated histones H3 and H4 on EVI1 promoter regions
after treatment with 5’Aza and TSA. The results were calculated and presented as described above, and comparing with and without the
treatment. Statistical significance was estimated using the non-parametric Wilcoxon’s matched pairs test; P<0.05 was considered significant
(*), and P<0.01 strongly significant (**).
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lation and degradation of the protein in these cell lines is
different. Furthermore, in our study we identified a novel
alternatively spliced MDS1EVI1 that, together with the
previously described EVI1 transcripts, might codify to the
same sized protein EVI1-FL. However, it is difficult to
know whether all these transcripts are used or not because
all cell lines with EVI1-FL protein express more than one
transcript, and we did not find any association between
any specific transcript and the protein. This highlights that
the mechanism of EVI1 protein regulation is complex and
still to be elucidated. Nevertheless, the fact that the EVI1
protein is present even if only one EVI1 transcript is over-
expressed supports the importance of the detection of
EVI1 expression status at diagnosis in AML patients, as
indicated by the new World Health Organization classifi-
cation.30 Moreover, AML cell lines over-expressed tran-
scripts -1A, -1B, -1C, and -1D, whereas cell lines with
CML-BP had only EVI1-1B over-expression as a common
feature. This might indicate that the mechanisms of EVI1
over-expression may depend on the action of different
transcription factors in the promoter of this gene, opening
directions for future studies.
In order to investigate other mechanisms of EVI1 over-
expression, we analyzed the role that epigenetic modifica-
tions could have in the regulation of the EVI1 gene. The
loci showed no methylation in either CD34+ progenitor
cells (high EVI1 expression) or normal bone marrow and
peripheral blood samples (very low EVI1 expression).
These results strongly suggest that DNA methylation mod-
ifications do not have a role in the normal regulation of
EVI1 expression during the process of differentiation of
hematopoietic cells, and that EVI1 promoter hypomethyla-
tion cannot be the mechanism of EVI1 over-expression.
However, we detected the absence of normal basal expres-
sion of EVI1 and MDS1EVI1 in patients’ samples and cell
lines, and several cell lines had 3q rearrangements and no
EVI1 over-expression; we, therefore, hypothesized that
epigenetic aberrations could play a role in the regulation of
the expression of EVI1 in AML. We found an aberrant
hypermethylation pattern in cell lines with no
EVI1/MDS1EVI1 expression (Figure 2C), and treatment of
these cell lines with TSA in combination with 5-Aza
induced EVI1 expression (Figure 2B). However, there were
no significant changes in the methylation status after the
treatment, suggesting that other epigenetic mechanisms
could be involved (Figure 2D). Our results showed that his-
tone modifications could be a mechanism that contributes
to silencing the normal basal expression of the EVI1 locus
in the leukemic cells (Figure 3 A-B). An important observa-
tion in this study is the active pattern of H4 and especially
of H3 in the HEL and TF-1 cell lines which over-express
EVI1. Of note, treatment of cell lines with no EVI1 expres-
sion induced expression of this gene and increased acetyla-
tion of both histones H3 and H4 on the EVI1 promoter
(Figure 3C). We also found that the AML cell lines with
DNA methylation and no EVI1 expression displayed
reduced H3K4me3. These data support the results of recent
studies in which it was observed that in AML there is an
inverse correlation between DNA methylation and the
H3K4 trimethylation pattern compared with unmethylated
samples.31-33 The epigenetic modifications H3K4me3 and
H3K27me3 are of particular interest as these modifications
are catalyzed by trithorax and polycomb-group proteins,
respectively, which have key developmental functions.
H3K4me3 methylation positively regulates transcription
by recruiting nucleosome remodeling enzymes and histone
acetylases, while H3K27me3 methylation negatively regu-
lates transcription by promoting a compact chromatin
structure. It has been described that the most highly con-
served non-coding elements in mammalian genomes clus-
ter within regions enriched for genes encoding develop-
mentally important transcription factors, such as EVI1,34
suggesting that these transcription factors could have key
epigenetic regulatory roles in development. Mapping his-
tone methylation patterns in mouse embryonic stem cells
showed that EVI1 has an open chromatin structure with a
H3K4me3 pattern, as we observed in our EVI1-expressing
cell lines, suggesting that this mechanism is involved in its
regulation in early hematopoietic cells. Our results support
the concept that the same mechanism could be involved in
the leukemic cells.34 Taken together, the histone modifica-
tions could explain the atypical expression pattern of both
cell lines and patients’ samples with no EVI1 expression.
This is of special interest since patients with no basal
expression of EVI1 tend to have a better overall survival
rate in comparison with cases with either expression or
over-expression (Figure 1). Nevertheless, prospective stud-
ies are needed to clarify the role of histone modifications in
EVI1 regulation.
In summary, our results confirm that EVI1 over-expres-
sion is an adverse prognostic factor in AML, and corrobo-
rate the necessity of quantifying EVI1 and MDS1EVI1
expression during the diagnosis of AML in younger
patients, mostly in cases with 3q aberrations, monosomy
7, MLL rearrangements, and in the subgroup with a normal
karyotype and no NPM1 mutations. Notably, we found
that the total absence of EVI1 expression may be associat-
ed with a better outcome in AML patients, and that this
atypical pattern may be regulated by epigenetic mecha-
nisms. Further studies are needed to elucidate the preva-
lence, prognostic impact, and the significance of no basal
EVI1 expression in the leukemic transformation of AML.
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